| A | |
| AI | Avian influenza |
| Anti-HBs | Antibody to Hepatitis B Surface Antigen |
| AEFI | Adverse Event Following Immunisation |
| aP | Acellular pertussis |
| B | |
| BCG | Bacille Calmette–Guérin |
| bNAb | Broadly Neutralizing Antibody |
| bOPV | Bivalent oral poliovirus vaccine |
| C | |
| cAD3-EBOZ | Chimpanzee Adenovirus Type 3–Vectored Ebola Vaccine |
| CCEEV | Cell culture- or embryonated egg-based vaccine |
| CDC | Centers for Disease Control and Prevention |
| CDI | Clostridioides difficile Infection |
| CDT | Binary Toxin (C. difficile transferase) |
| CFR | Case fatality rate |
| cGvHD | Chronic graft-versus-host disease |
| CHIKV | Chikungunya virus |
| COPD | Chronic Obstructive Pulmonary Disease |
| CRS | Congenital rubella syndrome |
| CSP | Circumsporozoite protein |
| cVDPV | Circulating vaccine-derived poliovirus |
| D | |
| DCA | Drug Control Authority |
| DENV | Dengue virus |
| DHF | Dengue haemorrhagic fever |
| DSS | Dengue shock syndrome |
| DTPa/dTpa | Diphtheria-tetanus-pertussis |
| E | |
| EBOV | Ebola virus |
| EPI | Expanded Programme of Immunisation |
| eRIG | Equine rabies immunoglobulin |
| EVD | Ebola virus disease |
| G | |
| GBS | Guillain-Barré syndrome |
| H | |
| HA | Haemagglutinin |
| HAART | Highly Active Antiretroviral Therapy |
| HAV | Hepatitis A Virus |
| HBIg | Hepatitis B immunoglobulin |
| HBV | Hepatitis B virus |
| HBsAg | Hepatitis B Surface Antigen |
| HCW | Healthcare worker |
| Hib | Haemophilus influenzae type b |
| HIV | Human immunodeficiency virus |
| hRIG | Human rabies immunoglobulin |
| HPV | Human papilloma virus |
| HPAI | Highly pathogenic avian influenza |
| HSCT | Hematopoietic stem cell transplantation |
| I | |
| ICH | Immunocompromised Hosts |
| ICVP | International Certificate of Vaccination or Prophylaxis |
| ID | Intradermal |
| IDU | Injecting drug users |
| Ig | Immunoglobulin |
| IgG | Immunoglobulin G |
| IHR | International Health Regulations |
| IIV | Inactivated influenza vaccine |
| IM | Intramuscular |
| IM NHIg | Intramuscular normal human immunoglobulin |
| IPV | Inactivated poliovirus vaccine |
| IPD | Invasive pneumococcal disease |
| ITH | International Travel and Health |
| IV | Intravenous |
| J | |
| JE | Japanese encephalitis |
| L | |
| LAIV | Live attenuated influenza vaccine |
| LPAI | Low pathogenic avian influenza |
| M | |
| MADRAC | Malaysian Adverse Drug Reaction Advisory Committee |
| MCV | Measles containing vaccine |
| MenACWY | Meningococcal ACWY |
| MMR | Measles-mumps-rubella |
| MSM | Men who have sex with men |
| mAb | Monoclonal antibody |
| N | |
| NA | Neuraminidase |
| NHIg | Normal human immunoglobulin |
| NHP | Nonhuman Primates |
| NK | Natural killer cells |
| nOPV2 | Novel oral poliovirus type 2 vaccine |
| NPRA | National Pharmaceutical Regulatory Agency |
| O | |
| OCV | Oral Cholera Vaccine |
| OPV | Oral poliovirus vaccine |
| P | |
| PCV | Pneumococcal conjugate vaccine |
| PfCSP | Plasmodium falciparum Circumsporozoite Protein |
| PEP | Post-exposure prophylaxis |
| PIZV | Purified Inactivated Zika Vaccine |
| PLHIV | People living with HIV |
| PPSV | Pneumococcal polysaccharide vaccine |
| PrEP | Pre-exposure prophylaxis |
| PRH | Product Registration Holder |
| prM | Pre-membrane protein |
| R | |
| RABV | Rabies virus |
| RCV | Rubella-containing vaccine |
| RIg | Rabies Immunoglobulin |
| RNA | Ribonucleic acid |
| RSV | Respiratory syncytial virus |
| RSVPreF3 | Respiratory Syncytial Virus Pre-fusion F protein |
| rVSV | Recombinant vesicular stomatitis virus |
| RZV | Recombinant zoster vaccine |
| S | |
| SC | Subcutaneous |
| SOT | Solid organ transplant |
| STD | Sexually Transmitted Disease |
| STI | Sexually transmissible infection |
| T | |
| TcdA | Clostridioides difficile Toxin A |
| TcdB | Clostridioides difficile Toxin B |
| Tdap | Tetanus, diphtheria and pertussis vaccine |
| Td | Tetanus and diphtheria vaccine |
| TB | Tuberculosis |
| TIG | Tetanus Immunoglobulin (Human Tetanus Immunoglobulin) |
| TIV | Trivalent Inactivated Influenza Vaccine |
| TST | Tuberculin Skin Test |
| Ty21a | Live attenuated oral Salmonella Typhi vaccine strain Ty21a |
| V | |
| VAPP | Vaccine associated paralytic poliomyelitis |
| VCD | Virologically confirmed dengue |
| VE | Vaccine efficacy |
| VLP | Virus-like particle |
| VZIg | Varicella Zoster Immunoglobulin |
| VZV | Varicella-zoster virus |
| W | |
| WHO | World Health Organization |
| WPV | Wild poliovirus |
| Y | |
| YF | Yellow Fever |
